TABLE OF CONTENTS

HIGHLIGHTS

359  Selected Articles from This Issue

REVIEWS

361  The MEK/ERK Network as a Therapeutic Target in Human Cancer
    Renee Barbosa, Lucila A. Acevedo, and Ronen Marmorstein

375  Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?
    Louisa Taylor, Ian D. Kerr, and Beth Coyle

388  Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer
    Tzuriel Sapir, David Shifteh, Moshe Pahmer, Sanjay Goel, and Radhashree Maitra

CANCER GENES AND NETWORKS

403  Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer

414  MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers
    Evelien Schafsma, Yanding Zhao, Lanjing Zhang, Yong Li, and Chao Cheng

429  G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-κB Signaling Pathway
    Ting Sun, Keqiang Zhang, Rajendra P. Pangeni, Jun Wu, Wendong Li, Yong Du, Yuming Guo, Shyambabu Chaurasiya, Leonidas Arvanitis, and Dan J. Raz

441  N-Acetyl-L-cysteine Promotes Ex Vivo Growth and Expansion of Single Circulating Tumor Cells by Mitigating Cellular Stress Responses
    Teng Teng, Mohamed Kamal, Obhana Iriondo, Yonatan Amzaleg, Chunqing Luo, Amal Thomas, Grace Lee, Ching-Ju Hsu, John D. Nguyen, Irene Kang, James Hicks, Andrew Smith, Richard Sposto, and Min Yu

MCN/Rapid IMPACT

395  Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

CANCER “-OMICS”

451  5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells
    Brian M. Reilly, Timothy Luger, Soo Park, Chan-Wang Jey Loo, Edahi Gonzalez-Avalos, Emily C. Wheeler, Minjung Lee, Laura Williamson, Tiffany Tanaka, Dinh Diep, Kun Zhang, Yun Huang, Anjana Rao, and Rafael Bejar

465  Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing
    Russell Bonneville, Anoosha Paruchuri, Michele R. Wing, Melanie A. Krook, Julie W. Reeser, Hui-Zi Chen, Thuy Dao, Eric Samorodnitsky, Amy M. Smith, Lianbo Yu, Nicholas Nowacki, Wei Chen, and Sameek Roychowdhury
### TABLE OF CONTENTS

#### METABOLISM

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>475</td>
<td>Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum</td>
<td>Kathryn L. Penney, Svitlana Tyekucheva, Jacob Rosenthal, Habiba El Fandy, Ryan Carelli, Stephanie Borgstein, Giorgia Zadra, Giuseppe Nicolò Fanelli, Lavinia Stefanizzi, Francesca Giunchi, Mark Pomerantz, Samuel Peisch, Hannah Coulson, Rosina Lis, Adam S. Kibel, Michelangelo Fiorentino, Renato Umeton, and Massimo Loda</td>
</tr>
</tbody>
</table>

#### SIGNAL TRANSDUCTION AND FUNCTIONAL IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>485</td>
<td>AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors</td>
<td>Kavya Ramkumar, C. Allison Stewart, Kasey R. Cargill, Carminia M. Della Corte, Qi Wang, Li Shen, Lixia Diao, Robert J. Cardnell, David H. Peng, B. Leticia Rodriguez, You-Hong Fan, John V. Heymach, Jing Wang, Carl M. Gay, Don L. Gibbons, and Lauren A. Byers</td>
</tr>
</tbody>
</table>

#### TUMOR MICROENVIRONMENT AND IMMUNOBIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>498</td>
<td>A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade</td>
<td>Yelena Lazdun, Han Si, Todd Creasy, Koustubh Ranade, Brandon W. Higgs, Katie Streicher, and Nicholas M. Durham</td>
</tr>
<tr>
<td>507</td>
<td>Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules</td>
<td>Yasuyo Sano, Toshimi Yoshida, Min-Kyung Choo, Yanek Jiménez-Andrade, Kathryn R. Hill, Katia Georgopoulos, and Jin Mo Park</td>
</tr>
<tr>
<td>516</td>
<td>Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity</td>
<td>Nikunji Gevariya, Gabriel Lachance, Karine Robitaille, Charles Joly Beauparlant, Lisanne Beaudoin, Éric Fournier, Yves Fradet, Arnaud Droit, Pierre Julien, André Marette, Alain Bergeron, and Vincent Fradet</td>
</tr>
<tr>
<td>528</td>
<td>Hypoxic Induction of Exosome Uptake through Proteoglycan-Dependent Endocytosis Fuels the Lipid Droplet Phenotype in Glioma</td>
<td>Myriam Cerezo-Magaña, Helena C. Christianson, Toin H. van Kuppevelt, Karin Forsberg-Nilsson, and Mattias Belting</td>
</tr>
</tbody>
</table>

### ABOUT THE COVER

DNA methylation is commonly dysregulated in a wide array of cancers, and numerous therapeutics have been developed to target this pathway. 5-Azacytidine is a DNA hypomethylating agent that can be particularly effective treatment in TET2-mutated myelodysplastic syndrome patients. The cover depicts hexagonal bins representing the density of CpG loci in a differential analysis of DNA methylation comparing targeted bisulfite sequencing data from TET2 wild-type and TET2 knockout human erythroleukemia cell lines (density gradient from red to blue, with red indicating larger number of CpG loci falling within the hexagonal bin and blue indicating a lesser number). The authors found that TET2 is essential for maintaining low levels of DNA methylation at erythroid-specific transcriptional enhancers, and that 5-Azacytidine can counteract aberrant hypermethylation of these enhancers when TET2 is mutated. For more information, see the article on page 451.